Amgen drug cuts small cell lung cancer death risk by 40%
1. Amgen's Imdelltra shows 40% lower death risk versus chemotherapy in trial. 2. Positive interim results may boost AMGN's market position in oncology.
FAQ
Why Bullish?
The strong trial results for Imdelltra indicate potential market advantage. Historical launches of successful oncology drugs have often led to significant stock price increases.
How important is it?
The article discusses pivotal clinical trial results that are likely to influence AMGN's stock performance positively.
Why Short Term?
The immediate market reaction to positive trial results can drive short-term stock appreciation, as seen with similar drug announcements.